Johnson Matthey Plc

Biologic therapies have dominated oncology pipeline news this month, with US submissions from Merck & Co. Inc. , AstraZeneca PLC , Immunomedics Inc. , and Y-mAbs Therapeutics Inc. ; breakthrough d

Immunomedics Inc. executives are avoiding drawing any connection between good manufacturing practice issues raised in a pre-license site inspection report of the firm’s Morris Plains, New Jersey, fac

Exhibit 1 Top Alliances In June/July 2015 (Potential Deal Value in $M) *Potential deal value is the sum of up-front fees plus pre-commercialization money. SOURCE: Strategic Transactions Exhibit 2 Top

Every little helps. A new ruling on the patents for Shire's top-selling drug Vyvanse will help bolster the company's case that AbbVie's recent takeover offer undervalues the firm. A US district court